Description
CJC-1295 no DAC + Ipamorelin is a peptide blend combining a short-acting GHRH analog with a ghrelin mimetic, studied in controlled laboratory environments for its dual-pathway activation of GHRH and ghrelin receptor signaling within the same experimental model. CJC-1295 no DAC engages the GHRH receptor with a half-life of approximately 30 minutes, producing a short, defined signaling window that mimics the pulsatile character of endogenous GHRH. Ipamorelin activates GHSR-1a through a Gq-coupled calcium cascade — a mechanistically independent route that, when combined with GHRH receptor input, allows researchers to study how dual-pathway stimulation influences GH pulse amplitude and timing. The blend is the primary tool for researchers asking questions about pulsatile GH release pattern research that neither compound can address individually.
Key Characteristics
- Activates two mechanistically independent receptor systems simultaneously — GHRHR via CJC-1295 no DAC, and GHSR-1a via Ipamorelin — creating an experimental condition that requires parallel single-compound control arms to distinguish pathway-specific contributions from interaction effects
- The no DAC format is the appropriate choice for pulsatile signaling models — its short half-life maintains the pulse-to-pulse dynamics that sustained-release formats would obscure
- Ipamorelin’s high GHSR-1a selectivity keeps the ghrelin pathway input clean — it does not significantly activate ACTH or cortisol-related off-target pathways at research-relevant concentrations, reducing confounding variables in GH-focused models
- Downstream IGF-1 production is frequently measured alongside GH release in models using this blend — the relationship between dual-pathway pulse amplitude and IGF-1 output is itself a research variable
- Supplied as a combined lyophilized powder; researchers requiring independent compound control in study design may prefer the standalone formats
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. Because this blend contains two peptide components with different structural properties, consistent cold-chain handling is particularly important for maintaining the integrity of both compounds across experimental batches. Avoid repeated freeze-thaw cycles.
FAQs
What is the CJC-1295 no DAC + Ipamorelin blend used for in research?
The blend is used in growth hormone signaling research models where simultaneous activation of both the GHRH receptor and the ghrelin receptor is the experimental goal. Researchers use it to study how dual-pathway input influences GH pulse amplitude, release timing, and downstream IGF-1 signaling — questions that require both compounds present in the same model.
Why use the no DAC format specifically in this blend?
CJC-1295 no DAC has a half-life of approximately 30 minutes, which preserves the pulsatile character of GHRH signaling. The blend is primarily studied for pulsatile release pattern research — using the DAC format would extend GHRH receptor engagement beyond the pulse window and change the research question from pulsatile dynamics to sustained stimulation. For sustained dual-pathway models, the CJC-1295 DAC + Ipamorelin format is the more appropriate choice.
How does this blend differ from studying CJC-1295 and Ipamorelin separately?
When administered together, the two compounds activate both the GHRH and ghrelin receptor pathways simultaneously. Research consistently documents additive GH release from dual-pathway activation that neither compound produces alone. Studying them separately isolates each pathway; the blend specifically addresses how the two pathways interact — a distinct research question that requires both compounds present at the same time.
